Blood Count Measures in Acute Lymphoblastic Leukemia Patients
Studies whether blood count measures predict response to induction chemotherapy in leukemia.
Plain-language title generated from the registry record
Registry title: Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
Key facts
- Where
- Sohag, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people newly diagnosed with acute lymphoblastic leukemia (ALL). It looks at whether blood count results can predict the response to the first chemotherapy.
- Age
- 5 Years to 50 Years
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed acute lymphoblastic leukemia (ALL).
- Earlier treatment
- People already on treatment for ALL cannot join.
Main reasons for not taking part
- Other cancers
- ALL already on therapy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 50 years old?
Source: NCT06746571, who can take part
Where in Egypt
- Sohag University HospitalSohag, EgyptContact: Magdy M Amin, professorNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sohag University
- Trial code
- NCT06746571
- Record updated
- 24 December 2024
- Original description
Role of cbc indices in acute lymphoblastic leukemia patients to explore the prognostic role of them in prediction the response to induction chemotherapyRead full original descriptionShow less
Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
Role of cbc indices in acute lymphoblastic leukemia patients to explore the prognostic role of them in prediction the response to induction chemotherapy
Inclusion: patients newly diagnosed ALL.
Exclusion: ALL on therapy; others malignanices.